We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Capillary and Venous Blood Sampling Compared for Coagulation Assays

By LabMedica International staff writers
Posted on 17 Mar 2022
Print article
Image: The ACL-TOP 750 LAS coagulation analyzer (Photo courtesy of Werfen)
Image: The ACL-TOP 750 LAS coagulation analyzer (Photo courtesy of Werfen)

Clinical laboratories offer a wide range of coagulation assays used in the diagnosis and management of patients with hemostatic disorders, preoperative screening, or anticoagulation therapy monitoring.

The request from clinicians for capillary blood collection for other routine coagulation test, such as International Normalized Ratio, prothrombin time, activated partial thromboplastin time, and thrombin time, remains significant in particular from those involved in pediatrics. Capillary sampling offers a less invasive method for blood collection than venipuncture, which makes it more suitable for neonates, young children as well as for adult patients with poor venous access or severe anxieties concerning blood sampling.

Diagnostic Laboratorians at the University Medical Center Utrecht (Utrecht, The Netherlands) performed a method comparison between capillary and venous blood sampling for routine coagulation assays. Both venous and capillary (finger stick) blood samples were collected from 188 healthy volunteers and patients. In citrate plasma, International Normalized Ratio (INR), prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen, and D-dimer were measured according to routine protocols using the ACL-TOP 750 LAS (Werfen, Bedford, MA, USA) coagulation analyzer. Regression analysis was performed and the mean relative difference between capillary and venous sampling was reflected to the total allowable error.

The scientists reported that there was a strong correlations and acceptable variations, using the total allowable error (TEa) as decision limit, were found for INR, PT, TT, fibrinogen, and D-dimer between capillary and venous sampling, However, capillary sampling resulted in significant shorter APTT values when using the standard APTT-SP Liquid reagent with a mean bias of −10.4%.. The mean relative difference of TT and fibrinogen was −1.7% and −3.7%, respectively, but were considered acceptable variations using the TEa as a decision limit. D-dimer showed a mean relative difference of 1.2%], which fell within the range of acceptable variation.

The authors concluded that strong correlations and acceptable variations were found for INR, PT, TT, fibrinogen, and D-dimer between capillary and venous sampling. However, capillary sampling resulted in significantly shorter APTT values when using the standard APTT-SP Liquid reagent. Based on these results, capillary blood sampling proved to be an alternative blood withdrawal method for routine coagulation assays, with the exception of APTT, if a venipuncture is unavailable. The study was originally published online on February 3, 2022, in the journal Clinical Biochemistry.

Related Links:
University Medical Center Utrecht 
Werfen 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.